Qing Song Health Co.,Ltd. (TPE:6931)
64.30
+0.90 (1.42%)
At close: Dec 19, 2025
Qing Song Health Revenue
Qing Song Health had revenue of 284.49M TWD in the quarter ending September 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to 1.08B, up 12.56% year-over-year. In the year 2024, Qing Song Health had annual revenue of 982.56M with 13.11% growth.
Revenue (ttm)
1.08B
Revenue Growth
+12.56%
P/S Ratio
3.96
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 982.56M | 113.90M | 13.11% |
| Dec 31, 2023 | 868.66M | 231.98M | 36.43% |
| Dec 31, 2022 | 636.69M | 279.15M | 78.08% |
| Dec 31, 2021 | 357.54M | 117.30M | 48.83% |
| Dec 31, 2020 | 240.24M | 115.74M | 92.97% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals Co., LTD. | 21.10B |
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Center Laboratories | 1.57B |
| Oneness Biotech | 117.33M |
| Polaris Group | 70.83M |
| Lumosa Therapeutics | 42.59M |
| Caliway Biopharmaceuticals | 34.99M |